|
For the quarter ended Dec 18, consolidated net sales stood at Rs 694.43 crore up by 17% YoY. OPM stood at 18.9% down by 30 bps thus restricting the OP growth to 15% to Rs 131.28 crore. Other income stood at Rs 3.30 crore down by 15%. Interest cost and depreciation cost stood at Rs 16.09 crore and Rs 47.04 crore respectively. PBT stood at Rs 71.45 crore up by 9% YoY. After providing total tax of Rs 25.63 crore and loss of share of associates of Rs 0.37 crore, consolidated PAT for Dec 18 quarter stood at Rs 45.45 crore up by 14% YoY.
For the quarter, sales from the Amesa geography stood at Rs 253.82 crore, up by 13% YoY and accounted for 35% of the total sales. PBIT from the same stood at Rs 36.50 crore up by 3% YoY and accounted for 42% of total PBIT.
For the quarter, sales from the EAP geography stood at Rs 172.33 crore, up by 23% YoY and accounted for 24% of total sales and PBIT from the same stood at Rs 32.06 crore up by 38% YoY with PBIT margin at 18.6% as compared to 16.6% for Dec 17 quarter.
For the quarter, sales from the America geography stood at Rs 147.66 crore and PBIT from the same stood at Rs 16.52 crore up down by 6% YoY. PBIT margin stood at 11.2% as compared to 13.9% for Dec 17 quarter.
For the quarter, sales from the EU geography stood at Rs 143.87 crore up by 21% YoY and PBIT stood at Rs 1.63 crore as compared to loss of Rs 1.33 crore for Dec 17 quarter with PBIT margin of 11.2%
Overall updates
The quarter has seen robust revenue growth in all the regions, helped by both oral and non-oral care categories
The Indian Pharma regulation issues have been addressed by the industry and expect volumes to see an uptick going forward. Have a strong order pipeline in India
A new laminator in India commenced production in the month of December 2018.
Net Debt as at December 2018 is Rs 615 crore as compared to Rs 700 crore on Sep 18.
ROE and ROCE on TTM basis is at 14.8% and 16.8% respectively as compared to 15.0% and 16.8%, respectively, in March 2018.
|